$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000100069421000016 Filed on August 05, 2021

Income Statement

Concept	2021 Q2	2020 Q2	2020 Q1
Revenue	$298.0M	$35.54M	$3.377M
YoY Change	738.59%	958.62%	-15.19%
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$298.0M
YoY Change
Gross Profit Margin	100.0%
Selling, General & Admin	$73.16M	$17.70M	$9.400M
YoY Change	313.34%	84.38%	8.05%
% of Gross Profit	24.55%
Research & Development	$570.7M	$34.85M	$16.90M
YoY Change	1537.73%	14.56%	-52.37%
% of Gross Profit	191.49%
Depreciation & Amortization	$2.427M	$1.000M	$900.0K
YoY Change	142.7%	-50.0%	-52.63%
% of Gross Profit	0.81%
Operating Expenses	$570.7M	$34.85M	$16.90M
YoY Change	1537.73%	14.56%	-52.37%
Operating Profit	-$345.8M	-$17.03M	-$22.90M
YoY Change	1931.06%	-53.56%	-43.07%
Interest Expense	$5.968M	$3.403M	$3.403M
YoY Change	75.37%	0.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	$3.028M	$2.612M	$0.00
YoY Change	15.93%	-32750.0%	-100.0%
Pretax Income	-$348.8M	-$17.52M	-$25.90M
YoY Change	1890.58%	-55.76%	-40.05%
Income Tax	$3.548M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$352.3M	-$17.52M	-$25.86M
YoY Change	1910.83%	-55.76%	-40.15%
Net Earnings / Revenue	-118.22%	-49.3%	-765.89%
Basic Earnings Per Share	-$4.75	-$0.30
Diluted Earnings Per Share	-$4.75	-$0.30	-$583.3K
COMMON SHARES
Basic Shares Outstanding	74.12M shares	58.62M shares
Diluted Shares Outstanding	74.12M shares	58.62M shares

Balance Sheet

Concept	2021 Q2	2020 Q2	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.075B	$502.3M	$237.4M
YoY Change	313.08%	597.64%	136.93%
Cash & Equivalents	$2.075B	$424.4M	$187.2M
Short-Term Investments	$1.754B	$152.1M	$150.4M
Other Short-Term Assets	$208.7M	$134.1M	$17.90M
YoY Change	55.67%	251.05%	-22.84%
Inventory
Prepaid Expenses
Receivables	$71.36M		$0.00
Other Receivables	$0.00		$0.00
Total Short-Term Assets	$2.355B	$636.4M	$255.2M
YoY Change	270.06%	477.48%	106.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$213.2M	$115.4M	$10.80M
YoY Change	84.78%	479.77%	-59.96%
Goodwill	$134.3M	$118.8M
YoY Change	13.0%
Intangibles	$5.281M	$5.250M
YoY Change	0.59%
Long-Term Investments
YoY Change
Other Assets	$40.37M	$55.96M	$7.000M
YoY Change	-27.86%	2698.05%	-40.34%
Total Long-Term Assets	$394.6M	$295.8M	$72.90M
YoY Change	33.38%	273.54%	-25.56%
TOTAL ASSETS
Total Short-Term Assets	$2.355B	$636.4M	$255.2M
Total Long-Term Assets	$394.6M	$295.8M	$72.90M
Total Assets	$2.750B	$932.2M	$328.1M
YoY Change	194.95%	392.2%	48.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$74.00M	$9.242M	$2.500M
YoY Change	700.64%	114.93%	-59.35%
Accrued Expenses	$249.2M	$38.69M	$12.00M
YoY Change	544.04%	92.49%	-13.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$98.38M
YoY Change
Total Short-Term Liabilities	$1.652B	$213.3M	$19.00M
YoY Change	674.16%	414.05%	-39.67%
LONG-TERM LIABILITIES
Long-Term Debt	$331.9M	$321.3M	$321.0M
YoY Change	3.31%	0.44%	0.47%
Other Long-Term Liabilities	$20.57M	$10.73M	$12.10M
YoY Change	91.79%	-20.56%	-30.71%
Total Long-Term Liabilities	$20.57M	$10.73M	$333.1M
YoY Change	91.79%	-96.78%	1807.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.652B	$213.3M	$19.00M
Total Long-Term Liabilities	$20.57M	$10.73M	$333.1M
Total Liabilities	$2.004B	$547.9M	$352.0M
YoY Change	265.78%	46.14%	-5.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.449B	-$1.499B
YoY Change	63.36%
Common Stock	$747.0K	$612.0K
YoY Change	22.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$47.21M	$2.638M
YoY Change	1689.42%
Treasury Stock Shares	424.1K shares	$51.41K
Shareholders Equity	$745.6M	$184.5M	-$23.97M
YoY Change
Total Liabilities & Shareholders Equity	$2.750B	$932.2M	$328.1M
YoY Change	194.95%	392.2%	48.25%

Cashflow Statement

Concept	2021 Q2	2020 Q2	2020 Q1
OPERATING ACTIVITIES
Net Income	-$352.3M	-$17.52M	-$25.86M
YoY Change	1910.83%	-55.76%	-40.15%
Depreciation, Depletion And Amortization	$2.427M	$1.000M	$900.0K
YoY Change	142.7%	-50.0%	-52.63%
Cash From Operating Activities	$144.4M	$115.6M	-$23.11M
YoY Change	24.91%	-485.33%	-54.33%
INVESTING ACTIVITIES
Capital Expenditures	-$15.13M	-$3.800M	-$100.0K
YoY Change	298.21%	660.0%	-87.5%
Acquisitions
YoY Change
Other Investing Activities	$2.240M	-$184.5M	-$57.60M
YoY Change	-101.21%	-7480.0%	-395.38%
Cash From Investing Activities	-$12.89M	-$188.2M	-$57.73M
YoY Change	-93.15%	-9510.0%	-408.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$185.9M
YoY Change			236.57%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-38.86M	416.6M	$185.9M
YoY Change	-109.33%		230.94%
NET CHANGE
Cash From Operating Activities	144.4M	115.6M	-$23.11M
Cash From Investing Activities	-12.89M	-188.2M	-$57.73M
Cash From Financing Activities	-38.86M	416.6M	$185.9M
Net Change In Cash	92.65M	344.0M	$105.0M
YoY Change	-73.07%	-1328.57%	333.22%
FREE CASH FLOW
Cash From Operating Activities	$144.4M	$115.6M	-$23.11M
Capital Expenditures	-$15.13M	-$3.800M	-$100.0K
Free Cash Flow	$159.5M	$119.4M	-$23.01M
YoY Change	33.61%	-504.75%	-53.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-26770
	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-2816046
	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 Firstfield Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg
	dei	Entity Address Country EntityAddressCountry	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20878
	dei	City Area Code CityAreaCode	(240)
	dei	Local Phone Number LocalPhoneNumber	268-2000
	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 per share
	dei	Trading Symbol TradingSymbol	NVAX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74484166	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2074880000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553398000	USD
CY2021Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	157649000	USD
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	46398000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	93880000	USD
CY2021Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	49989000	USD
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	262012000	USD
CY2021Q2	nvax	Unbilled Services UnbilledServices	21374000	USD
CY2020Q4	nvax	Unbilled Services UnbilledServices	0	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	162351000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	181264000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	2354992000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1248203000	USD
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1461000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1460000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	213186000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	179954000	USD
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5281000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5725000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	134294000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	135379000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	40373000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11758000	USD
CY2021Q2	us-gaap	Assets Assets	2749587000	USD
CY2020Q4	us-gaap	Assets Assets	1582479000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	73995000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	54332000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	249178000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	142468000	USD
CY2021Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1220073000	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	273228000	USD
CY2021Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	98383000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	105862000	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9887000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3782000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1651516000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	579672000	USD
CY2021Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	322746000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	322035000	USD
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	9193000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	40083000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20570000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13480000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	2004025000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	955270000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	2000000	shares
CY2021Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	2000000	shares
CY2021Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	570685000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74672351	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74248279	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71350365	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70953739	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	747000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	714000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3237085000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2535476000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2449235000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1874199000	USD
CY2021Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	424072	shares
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	396626	shares
CY2021Q2	us-gaap	Treasury Stock Value TreasuryStockValue	47205000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	41806000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4170000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7024000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	745562000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627209000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2749587000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1582479000	USD
CY2021Q2	us-gaap	Revenues Revenues	298017000	USD
CY2020Q2	us-gaap	Revenues Revenues	35538000	USD
	us-gaap	Revenues Revenues	745246000	USD
	us-gaap	Revenues Revenues	38915000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34846000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1163356000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51741000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	73161000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17719000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	136351000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27098000	USD
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	643846000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	52565000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1299707000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	78839000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-345829000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17027000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-554461000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39924000	USD
CY2021Q2	us-gaap	Investment Income Net InvestmentIncomeNet	369000	USD
CY2020Q2	us-gaap	Investment Income Net InvestmentIncomeNet	297000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	731000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	732000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	5968000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	3403000	USD
	us-gaap	Interest Expense InterestExpense	10807000	USD
	us-gaap	Interest Expense InterestExpense	6806000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2659000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2612000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3934000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2613000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-348769000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17521000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-568471000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43385000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3548000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6565000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-352317000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-17521000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-575036000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-43385000	USD
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.75
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.75
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74118000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74118000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58618000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58618000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73580000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73580000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51401000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51401000	shares
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-352317000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-17521000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-575036000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-43385000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	176000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-9000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	44000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	4527000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1115000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2845000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-731000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4527000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1291000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2854000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-687000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-347790000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16230000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-577890000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44072000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1039127000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	53123000	USD
CY2021Q2	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	1102000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4527000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-352317000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	745562000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-23971000	USD
CY2020Q2	nvax	Stock Issued During Period Value Preferred Stock Beneficial Conversion Increase Decrease StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease	0	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7932000	USD
CY2020Q2	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	8950000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2647000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	207845000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	176000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1115000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-17521000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	184526000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	627209000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	106183000	USD
	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	25201000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	7292000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	564859000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-9000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2845000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-575036000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	745562000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-186017000	USD
	nvax	Stock Issued During Period Value Preferred Stock Beneficial Conversion Increase Decrease StockIssuedDuringPeriodValuePreferredStockBeneficialConversionIncreaseDecrease	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11897000	USD
	nvax	Compensation Stock Issued Under Incentive Program CompensationStockIssuedUnderIncentiveProgram	8955000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	5145000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	393763000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	44000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-731000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-43385000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	184526000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-575036000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-43385000	USD
	nvax	Depreciation And Amortization Otherthan Right Of Use Asset DepreciationAndAmortizationOtherthanRightOfUseAsset	4727000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	106183000	USD
	nvax	Depreciation And Amortization Otherthan Right Of Use Asset DepreciationAndAmortizationOtherthanRightOfUseAsset	1905000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11897000	USD
	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	12707000	USD
	nvax	Operating And Finance Lease Write Off OperatingAndFinanceLeaseWriteOff	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3855000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1081000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-193004000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	61079000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	115212000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	27094000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	946845000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	157173000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	807497000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	92524000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	28932000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3884000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	164204000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2167000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	107608000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	159807000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	29750000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	128708000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-245946000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	199822000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	564859000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	393763000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26903000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8955000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	53618000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	538144000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	602540000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-348000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	276000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1474001000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	449394000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648738000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82180000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2122739000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	531574000	USD
	nvax	Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability	28826000	USD
	nvax	Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11037000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2753000	USD
	us-gaap	Interest Paid Net InterestPaidNet	10046000	USD
	us-gaap	Interest Paid Net InterestPaidNet	6094000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3017000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	Organization<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiaries, including Novavax AB and Novavax CZ, the “Company”) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The Company’s vaccine candidates, including both its coronavirus vaccine candidate, NVX-CoV2373, and its lead influenza vaccine candidate, NanoFlu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis and may elicit differentiated immune responses, which may be more efficacious than naturally occurring immunity or traditional vaccines. NVX-CoV2373 and NanoFlu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> include the use of the Company's proprietary Matrix-M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">™ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">adjuvant.</span>
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	4200000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	7000000.0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div>
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2074880000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553398000	USD
CY2021Q2	us-gaap	Security Deposit SecurityDeposit	1500000	USD
CY2020Q4	us-gaap	Security Deposit SecurityDeposit	1500000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2074880000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553398000	USD
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	46398000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	93880000	USD
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1461000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1460000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2122739000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	648738000	USD
CY2021Q2	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3500000	USD
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	6600000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	0	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	157640000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	157649000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	135379000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-1085000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	134294000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12688000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7407000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5281000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	13208000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7483000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5725000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	219000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	437000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	437000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	437000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	437000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	437000	USD
CY2021Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11400000	USD
CY2021Q2	nvax	Long Term Supply Agreement Incremental Borrowing Rate LongTermSupplyAgreementIncrementalBorrowingRate	0.065
CY2021Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	86600000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	214200000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2020Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2021Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1800000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000000.0	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	USD
CY2020Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	USD
CY2021Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
CY2021Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2021Q2	nvax	Increase Decrease Right Of Use Asset Obtained In Exchange For Operating Lease Liability IncreaseDecreaseRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7200000	USD
CY2016Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	10000000.0	USD
CY2016Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	325000000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	10000000.0	USD
CY2016Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P7Y
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	325000000	USD
CY2020Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	325000000	USD
CY2021Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2254000	USD
CY2020Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2965000	USD
CY2021Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	322746000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	322035000	USD
CY2021Q2	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0375
CY2021Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3047000	USD
CY2021Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3047000	USD
CY2020Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3047000	USD
CY2020Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3047000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	6094000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	6094000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	6094000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	6094000	USD
CY2021Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	356000	USD
CY2021Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	356000	USD
CY2020Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	356000	USD
CY2020Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	356000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	712000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	712000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	712000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	712000	USD
CY2021Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	3403000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	131.66
CY2020Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	3403000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	6806000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	6806000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	166.66
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	77.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	76.99
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	865000000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	121000000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	115000000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8000000	USD
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	53123000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7932000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	106183000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11897000	USD
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	230000000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2021Q2	us-gaap	Revenues Revenues	298017000	USD
CY2020Q2	us-gaap	Revenues Revenues	35538000	USD
	us-gaap	Revenues Revenues	745246000	USD
	us-gaap	Revenues Revenues	38915000	USD
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	262012000	USD
	nvax	Receivables Net Current Additions ReceivablesNetCurrentAdditions	1309924000	USD
	nvax	Receivables Current Net Deductions ReceivablesCurrentNetDeductions	1521947000	USD
CY2021Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	49989000	USD
CY2020Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	0	USD
	nvax	Unbilled Receivables Current Additions UnbilledReceivablesCurrentAdditions	499239000	USD
	nvax	Unbilled Receivables Current Deductions UnbilledReceivablesCurrentDeductions	477865000	USD
CY2021Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	21374000	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	273228000	USD
	nvax	Deferred Revenue Current Additions DeferredRevenueCurrentAdditions	1192483000	USD
	nvax	Deferred Revenue Current Deductions DeferredRevenueCurrentDeductions	245638000	USD
CY2021Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1220073000	USD
CY2021Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1200000000	USD
CY2021Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	7000000000.0	USD
CY2021Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M

Files In Submission

Name	View Source	Status
0001000694-21-000016-index-headers.html	Edgar Link	pending
0001000694-21-000016-index.html	Edgar Link	pending
0001000694-21-000016.txt	Edgar Link	pending
0001000694-21-000016-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvax-20210630.htm	Edgar Link	pending
nvax-20210630.xsd	Edgar Link	pending
nvax-20210630xex101.htm	Edgar Link	pending
nvax-20210630xex102.htm	Edgar Link	pending
nvax-20210630xex104.htm	Edgar Link	pending
nvax-20210630xex105.htm	Edgar Link	pending
nvax-20210630xex106.htm	Edgar Link	pending
nvax-20210630xex107.htm	Edgar Link	pending
nvax-20210630xex311.htm	Edgar Link	pending
nvax-20210630xex312.htm	Edgar Link	pending
nvax-20210630xex321.htm	Edgar Link	pending
nvax-20210630xex322.htm	Edgar Link	pending
nvax-20210630_cal.xml	Edgar Link	unprocessable
nvax-20210630_def.xml	Edgar Link	unprocessable
nvax-20210630_g1.jpg	Edgar Link	pending
nvax-20210630_g2.jpg	Edgar Link	pending
nvax-20210630_g3.jpg	Edgar Link	pending
nvax-20210630_htm.xml	Edgar Link	completed
nvax-20210630_lab.xml	Edgar Link	unprocessable
nvax-20210630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2021 Q2 Form 10-Q Financial Statement

#000100069421000016 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2021 Q2 Form 10-Q Financial Statement

#000100069421000016 Filed on August 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax